|
||||||||||||||||||||||||||
| SEC Info℠ | | | Home | | | Search | | | My Interests | | | Help | | | Sign In | | | Please Sign In | |||||||
|
||||||||||||||||||||||||||
As Of Filer Filing For·On·As Docs:Size Issuer Filing Agent 2/14/20 Bionik Laboratories Corp. 10-Q 12/31/19 65:4.3M Toppan Merrill/FA |
Document/Exhibit Description Pages Size
1: 10-Q Quarterly Report HTML 298K
2: EX-31.1 Certification -- §302 - SOA'02 HTML 23K
3: EX-31.2 Certification -- §302 - SOA'02 HTML 23K
4: EX-32.1 Certification -- §906 - SOA'02 HTML 20K
5: EX-32.2 Certification -- §906 - SOA'02 HTML 20K
15: R1 Document And Entity Information HTML 49K
45: R2 Condensed Consolidated Interim Balance Sheets HTML 92K
54: R3 Condensed Consolidated Interim Balance Sheets HTML 46K
(Parenthetical)
30: R4 Condensed Consolidated Interim Statements of HTML 73K
Operations and Comprehensive (Loss)
17: R5 Condensed Consolidated Interim Statements of HTML 85K
Changes in Shareholders' Equity
47: R6 Condensed Consolidated Interim Statements of Cash HTML 101K
Flows
56: R7 Nature of Operations and Going Concern HTML 35K
32: R8 Basis of Presentation HTML 24K
13: R9 Significant Accounting Policies HTML 36K
29: R10 Technology and Other Assets HTML 74K
16: R11 Prepaid Expenses and Other Receivables HTML 39K
48: R12 Inventories HTML 33K
57: R13 Equipment HTML 79K
28: R14 Notes Payable HTML 39K
14: R15 Related Party Transactions and Balances HTML 24K
46: R16 Share Capital HTML 78K
55: R17 Stock Options HTML 98K
31: R18 Warrants HTML 63K
12: R19 Commitments and Contingencies HTML 29K
41: R20 Subsequent Event HTML 21K
64: R21 Significant Accounting Policies (Policies) HTML 42K
27: R22 Technology and Other Assets (Tables) HTML 73K
23: R23 Prepaid Expenses and Other Receivables (Tables) HTML 40K
40: R24 Inventories (Tables) HTML 34K
63: R25 Equipment (Tables) HTML 78K
26: R26 Notes Payable (Tables) HTML 29K
22: R27 Share Capital (Tables) HTML 75K
38: R28 Stock Options (Tables) HTML 85K
65: R29 Warrants (Tables) HTML 64K
52: R30 Nature of Operations and Going Concern (Details) HTML 52K
42: R31 Basis of Presentation (Details) HTML 24K
18: R32 Significant Accounting Policies (Details) HTML 25K
33: R33 TECHNOLOGY AND OTHER ASSETS - Intangible assets HTML 47K
acquired (Details)
53: R34 TECHNOLOGY AND OTHER ASSETS - Additional HTML 23K
Information (Details)
43: R35 Prepaid Expenses and Other Receivables (Details) HTML 39K
19: R36 INVENTORIES- Schedule of Inventories (Details) HTML 21K
34: R37 INVENTORIES - Additional Information (Details) HTML 22K
51: R38 EQUIPMENT - Schedule of net equipment (Details) HTML 45K
44: R39 Equipment (Details) HTML 22K
61: R40 Notes Payable (Details) HTML 69K
35: R41 Notes Payable - Conversion of Notes Payable HTML 34K
(Details)
20: R42 Related Party Transactions and Balances (Details) HTML 41K
24: R43 SHARE CAPITAL - Common shares issued (Details) HTML 55K
62: R44 SHARE CAPITAL - Additional Information (Details) HTML 56K
36: R45 STOCK OPTIONS - Summary of stock options HTML 94K
outstanding and exercisable (Details)
21: R46 STOCK OPTIONS - Additional Information (Details) HTML 167K
25: R47 WARRANTS - Summary of continuity schedule HTML 39K
(Details)
60: R48 WARRANTS - Summary of common share purchase HTML 35K
warrants outstanding (Details)
37: R49 WARRANTS - Additional Information (Details) HTML 25K
50: R50 COMMITMENTS AND CONTINGENCIES - Additional HTML 52K
Information (Details)
58: R51 SUBSEQUENT EVENT - Additional Information HTML 27K
(Details)
59: XML IDEA XML File -- Filing Summary XML 112K
49: EXCEL IDEA Workbook of Financial Reports XLSX 66K
6: EX-101.INS XBRL Instance -- bnkl-20191231 XML 1.53M
8: EX-101.CAL XBRL Calculations -- bnkl-20191231_cal XML 106K
9: EX-101.DEF XBRL Definitions -- bnkl-20191231_def XML 393K
10: EX-101.LAB XBRL Labels -- bnkl-20191231_lab XML 793K
11: EX-101.PRE XBRL Presentations -- bnkl-20191231_pre XML 646K
7: EX-101.SCH XBRL Schema -- bnkl-20191231 XSD 150K
39: ZIP XBRL Zipped Folder -- 0001104659-20-020750-xbrl Zip 109K
Exhibit 31.1
CERTIFICATION PURSUANT TO SECTION 302
OF
THE SARBANES-OXLEY ACT OF 2002
I, Eric Dusseux, certify that:
1. I have reviewed this quarterly report on Form 10-Q of Bionik Laboratories Corp.;
2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4. The registrant's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal controls over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under my supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
c) Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report, our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
d) Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarterly(the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and
5. The registrant's other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of registrant's board of directors (or persons performing the equivalent functions):
a) all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and
b) any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal controls over financial reporting.
| Date: February 14, 2020 | /s/ Eric Dusseux | |
Chief Executive Officer | ||
(Principal Executive Officer) |
C:
| This ‘10-Q’ Filing | Date | Other Filings | ||
|---|---|---|---|---|
 | ||||
| Filed on: | 2/14/20 | 8-K | ||
| For Period end: | 12/31/19 | SD | ||
| List all Filings | ||||